Contact Us
Drug Search Results
More Filters [+]

HDM-2005

Alternative Names: HDM-2005, HDM 2005, HDM2005
Latest Update: 2024-09-26
Latest Update Note: Clinical Trial Update

Product Description

Injection HDM2005 is a type 1 new biological drug with global intellectual property rights developed and owned by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It is an antibody-conjugated drug (ADC) that targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1). Preclinical studies have shown that after entering the body, the antibody portion of HDM2005 specifically binds to target cells expressing tumor antigens. After being internalized by tumor cells, the cytotoxin is released intracellularly, thus completing the killing of tumor cells. Existing data show that HDM2005 has good drugability and safety. (Sourced from: https://www.moomoo.com/news/post/39046457/huadong-medicine-000963-sz-approval-obtained-for-clinical-trial-application?level=1&data_ticket=1724423598756466)

Mechanisms of Action: ROR1 Modulator

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HDM-2005

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions